Effect of an optimized treatment with insulin on platelet reactivity after discharge in patients with an acute coronary syndrome and hyperglycemia;Efecto del tratamiento optimizado con insulina en la reactividad plaquetaria tras el alta de pacientes hiperglucémicos con síndrome coronario agudo

Revista Espanola de Cardiologia

Volumn 67, Issue 1, 2014, Pages 22-27

  Vivas, David ^a   García Rubira, Juan C ^a   Bernardo, Esther ^a   Angiolillo, Dominick J ^a   Martín, Patricia ^a   Calle, Alfonso ^a   Núñez Gil, Iván ^a   MacAya, Carlos ^a   Fernández Ortiz, Antonio ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Acute coronary syndrome; Diabetes mellitus; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD GLUCOSE MONITORING; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; AGED; BLOOD; BLOOD CLOTTING PARAMETERS; COMPLICATION; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; THROMBOCYTE; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PLATELETS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES;

EID: 84891835971     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2013.05.021     Document Type: Article

References (32)

1. S.E. Capes, D. Hunt, K. Malmberg, and H.C. Gerstein Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview Lancet 355 2000 773 778
2. D. Vivas, J.C. García-Rubira, J.J. González-Ferrer, I. Núñez-Gil, N. Del Prado, and A. Fernández-Ortiz et al. Valor pronóstico de la primera glucemia en ayunas en comparación con la glucemia al ingreso en pacientes con síndrome coronario agudo Rev Esp Cardiol 61 2008 458 464
3. R. Sanjuán, J. Núñez, M.L. Blasco, G. Miñana, H. Martínez-Maicas, and N. Carbonell et al. Implicaciones pronósticas de la hiperglucemia de estrés en el infarto agudo de miocardio con elevación del ST. Estudio observacional prospectivo Rev Esp Cardiol 64 2011 201 207
4. A.M. Norhammar, L. Rydén, and K. Malmberg Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients Diabetes Care 22 1999 1827 1831
5. D.J. Angiolillo, E. Bernardo, C. Ramírez, M.A. Costa, M. Sabaté, and P. Jimenez-Quevedo et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 2006 298 304
6. G. Van den Berghe, P. Wouters, F. Weekers, C. Verwaest, F. Bruyninckx, and M. Schetz et al. Intensive insulin therapy in the critically ill patients N Engl J Med 345 2001 1359 1367
7. G. Van den Berghe, A. Wilmer, G. Hermans, W. Meersseman, P.J. Wouters, and I. Milants et al. Intensive insulin therapy in the medical ICU N Engl J Med 354 2006 449 461
8. K. Malmberg, L. Ryden, S. Efendic, J. Herlitz, P. Nicol, and A. Waldenström et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J Am Coll Cardiol 26 1995 57 65
9. N.W. Cheung, V.W. Wong, and M. McLean The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction Diabetes Care 29 2006 765 770
10. R.S. Wiener, D.C. Wiener, and R.J. Larson Benefits and risks of tight glucose control in critically ill adults: a meta-analysis JAMA 300 2008 933 944
11. S. Finfer, D.R. Chittock, S.Y. Su, D. Blair, D. Foster, V. Dhingra The NICE-SUGAR Study Investigators Intensive versus conventional glucose control in critically ill patients N Engl J Med 360 2009 1283 1297
12. D. Vivas, J.C. García-Rubira, E. Bernardo, D.J. Angiolillo, P. Martín, and A. Calle-Pascual et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo") Heart 97 2011 803 809
13. D. Vivas, J.C. García-Rubira, E. Bernardo, D.J. Angiolillo, P. Martín, and A. Calle-Pascual et al. Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study ("Control de HIperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo") J Thromb Thrombolysis 35 2013 165 174
14. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
15. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
16. K. Malmberg, L. Ryden, H. Wedel, K. Birkeland, A. Bootsma, and K. Dickstein et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Eur Heart J 26 2005 650 661
17. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, and M. Woodward et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
18. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr., J.T. Bigger, and J.B. Buse et al. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
19. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven et al. Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
20. J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, and M. Verschuren et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 33 2012 1635 1701
21. D.J. Angiolillo, E. Bernardo, M. Sabaté, P. Jimenez-Quevedo, M.A. Costa, and J. Palazuelos et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547
22. P.G. Steg, S.K. James, D. Atar, L.P. Badano, C. Blömstrom-Lundqvist, and M.A. Borger et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
23. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 32 2011 2999 3054
24. D.J. Angiolillo, P. Capranzano, J.L. Ferreiro, M. Ueno, D. Capodanno, and K. Dharmashankar et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy Thromb Haemost 106 2011 253 262
25. P.A. Gurbel, K.P. Bliden, W. Samara, J.A. Yoho, K. Hayes, and M.Z. Fissha et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study J Am Coll Cardiol 46 2005 1827 1832
26. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramírez, M. Sabaté, and P. Jimenez-Quevedo et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention Am J Cardiol 97 2006 38 43
27. A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, and M.W. Steffes et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
28. TIMI Study Group. Definitions used in TIMI-trials [citado 1 Ago 2009]. Disponible en: http://www.timi.org
29. J.M. García Acuña, E. González-Babarro, L. Grigorian Shamagian, C. Peña-Gil, R. Vidal Pérez, and A.M. López-Lago et al. La cistatina C aporta más información que otros parámetros de función renal en la estratificación del riesgo de los pacientes con síndrome coronario agudo Rev Esp Cardiol 62 2009 510 519
30. C. Stettler, S. Allemann, P. Jüni, C.A. Cull, R.R. Holman, and M. Egger et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials Am Heart J 152 2006 27 38
31. F.M. Turnbull, C. Abraira, R.J. Anderson, R.P. Byington, J.P. Chalmers, and W.C. Duckworth et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2009 2288 2298
32. T.N. Kelly, L.A. Bazzano, V.A. Fonseca, T.K. Thethi, K. Reynolds, and J. He Systematic review: glucose control and cardiovascular disease in type 2 diabetes Ann Intern Med 151 2009 394 403